Oncology Live®
Vol. 22/No. 24
Volume: 22
Issue: 24
Vol. 22/No. 23
Volume: 22
Issue: 23
Vol. 22/No. 22
Volume: 22
Issue: 22
Vol. 22/No. 21
Volume: 22
Issue: 21
Vol. 22/No. 20
Volume: 22
Issue: 20
Vol. 22/No. 19
Volume: 22
Issue: 19
Vol. 22/No. 18
Volume: 22
Issue: 18
Vol. 22/No. 17
Volume: 22
Issue: 17
Vol. 22/No. 16
Volume: 22
Issue: 16
Vol. 22/No. 15
Volume: 22
Issue: 15
Vol. 22/No. 14
Volume: 22
Issue: 14
Vol. 22/No. 13
Volume: 22
Issue: 13
Vol. 22/No. 12
Volume: 22
Issue: 12
Vol. 22/No. 11
Volume: 22
Issue: 11
Vol. 22/No. 10
Volume: 22
Issue: 10
Vol. 22/No. 09
Volume: 22
Issue: 09
Vol. 22/No. 08
Volume: 22
Issue: 08
Vol. 22/No. 07
Volume: 22
Issue: 07
Vol. 22/No. 06
Volume: 22
Issue: 06
Vol. 22/No. 5
Volume: 22
Issue: 05
Vol. 22/No. 4
Volume: 22
Issue: 04
Vol. 22/No. 03
Volume: 22
Issue: 03
Vol. 22/No. 02
Volume: 22
Issue: 02
Vol. 22/No. 01
Volume: 22
Issue: 01
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5